Aarvik Therapeutics
Hayward, California, United States · Biotechnology, Healthcare, Health Care
Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.
Key facts
- Headquarters
- Hayward, California, United States
- Employees
- 10
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Private
- Website
- aarviktx.com
- Company page
Recent activity at Aarvik Therapeutics
- : Aarvik Therapeutics Enters Partnership with Laurus Labs for MUTTA™ ADC Development in India.
- : Aarvik Therapeutics has secured a successful Series Seed 2 financing round. This funding will help advance the company's proprietary MUTTA™ platform and reach targeted research milestones.
- : Aarvik Therapeutics
- : Aarvik Therapeutics announces collaboration option exercise by ArriVent BioPharma (date Fundz recorded it)
- : Aarvik Therapeutics, Inc.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Aarvik Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Seed | Undisclosed |
| Nov 2024 | Seed | $1.2M |
| Sep 2021 | Venture | $8.3M |
Leadership
- Jagath Reddy Junutula, Director
- Pradeep Fernandes, Chief Operating Officer
Verified email and direct lines for Aarvik Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Aarvik Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Aarvik Therapeutics in the news
- Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference - Business Wire (Nov 02, 2026)
- Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 - Business Wire (Mar 17, 2026)
- Aarvik Therapeutics Announces Investment by Laurus Labs in Aarvik Series Seed 2 Round - Business Wire (Oct 08, 2025)
Companies similar to Aarvik Therapeutics
- BioLineRx Ltd · Biotechnology, Healthcare, Health Care, research, Therapeutics
- Retension Pharmaceuticals · Biotechnology, Healthcare, Health Care, Therapeutics
- Onward Therapeutics SA · Biotechnology, Health Care, research, Therapeutics
- Yarrow Bioscience · Biotechnology, Healthcare, Health Care, Therapeutics
- Cocrystal Pharma, Inc. · Biotechnology, Healthcare, Health Care, Therapeutics
About Aarvik Therapeutics: questions and answers
What does Aarvik Therapeutics do?
Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.
Where is Aarvik Therapeutics headquartered?
Aarvik Therapeutics is headquartered in Hayward, California, United States.
How many employees does Aarvik Therapeutics have?
Aarvik Therapeutics has about 10 employees.
Has Aarvik Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for Aarvik Therapeutics. The most recent, Seed of Undisclosed, was in Sep 2025.
What is the latest news on Aarvik Therapeutics?
On Nov 3, 2026, Aarvik Therapeutics Enters Partnership with Laurus Labs for MUTTA™ ADC Development in India.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy